{
    "2021-08-17": [
        [
            {
                "time": "2021-08-10",
                "original_text": "高瓴砍仓50%，最牛赛道变天了！",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "砍仓",
                        "凯莱英",
                        "医药"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-12",
                "original_text": "财信证券无炒股凯莱英谨慎推荐评级：小分子CDMO业务订单充足，新建产能陆续释放，目标价400.04-457.60元",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "CDMO",
                        "订单充足",
                        "产能释放"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-15",
                "original_text": "CRO/CDMO企业中报亮眼，药审中心新规“影响”几何？",
                "features": {
                    "keywords": [
                        "CRO",
                        "CDMO",
                        "中报",
                        "药审中心",
                        "新规"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-18",
                "original_text": "高瓴资本二季度减持路线图曝光！抛售A股医药、美股电商，释放了什么信号？ 减持股份",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "减持",
                        "医药",
                        "电商"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "电商"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-20",
                "original_text": "CXO赛道不香了？高瓴资本大幅减持凯莱英，持续重仓这两家药企 减持股份",
                "features": {
                    "keywords": [
                        "CXO",
                        "高瓴资本",
                        "减持",
                        "凯莱英"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-25",
                "original_text": "突然崩了，3800家公司下跌！究竟发生了什么？",
                "features": {
                    "keywords": [
                        "市场下跌",
                        "公司数量",
                        "原因分析"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "整体市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "[公司]凯莱英21H1净利4.29亿元 “订单充裕+产能加速”集聚爆发潜能",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "净利",
                        "订单充裕",
                        "产能加速"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}